Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verrica PharmaceuticalsSTU:1NE0 -0.31%49 Days Payable is 217.50 as of Mar. 2026, which is 31% below its 10-year median of 315.37. GuruFocus rates STU:1NE0 with a GF Score™ of 49/100 and a GF Value™ of €12.16 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Verrica Pharmaceuticals ranks better than 61.06% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1NE0 vs ENGN, PEPG, ONCY: Days Payable Comparison
For the Biotechnology subindustry, Verrica Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Verrica Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals (STU:1NE0) has a Days Payable of 217.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Verrica Pharmaceuticals and its competitors. This is 31% below median its historical median of 315.37. Over the past decade, Verrica Pharmaceuticals' Days Payable has ranged from 180.28 to 726.82. According to the industry distribution chart, Verrica Pharmaceuticals ranks #273 out of 701 companies in the Biotechnology industry, placing it in the top 38.9%.
Is Verrica Pharmaceuticals' Days Payable too high?
Verrica Pharmaceuticals' current Days Payable of 217.50 is 31% below median its 10-year median of 315.37. Over the past 10 years, this metric has ranged from a low of 180.28 to a high of 726.82. The Biotechnology industry median Days Payable is 112.84. Verrica Pharmaceuticals' value of 217.50 is 92.8% above this industry median. Based on the distribution chart, Verrica Pharmaceuticals ranks #273 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Verrica Pharmaceuticals has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Days Payable compare to ENGN and PEPG?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #273 out of 701 companies for Days Payable. This puts Verrica Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 112.84. Verrica Pharmaceuticals' value of 217.50 is 92.8% above this benchmark. Historically, Verrica Pharmaceuticals' own Days Payable has ranged from 180.28 to 726.82 over the past decade. While the company's 10-year median is 315.37 vs. the industry median of 112.84, Verrica Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verrica Pharmaceuticals's current Days Payable of 217.50 is 92.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Verrica Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verrica Pharmaceuticals's current Days Payable is 217.50, which is 31% below median its own 10-year median of 315.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €12.16, compared to a current price of €4.86 — trading 60.1% below its estimated fair value. The current Days Payable is 217.50, which is 31% below median its 10-year median of 315.37 and 92.8% above the Biotechnology industry median of 112.84. Verrica Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current Days Payable is 217.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.86 is trading 60.1% below its estimated GF Value™ of €12.16.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:1NE0:
Days Payable: 217.50 (31% below median its 10-year median of 315.37)
GF Value™: €12.16 vs. price of €4.86 (60.1% below fair value)
Industry Position: 92.8% above the Biotechnology median (#273 of 701)
No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
49GF Score
Get the complete analysis for STU:1NE0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1NE0 has been successfully added to your 
